Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database Sukhmani.

Slides:

Advertisements

Similar presentations

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Advertisements

Assessment of Lymph Node Ratio to Replace the pN Categories System of Classification of the TNM System in Esophageal Squamous Cell Carcinoma Yingjie.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Lymphovascular Invasion as a Prognostic Indicator in Stage I Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis Nathan M. Mollberg, DO,

Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S

Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis Sarah Cargnin, PhD,

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus Yang Zhao, MD, ZhiJun Dai,

The eighth edition TNM stage classification for lung cancer: What does it mean on main street? Frank C. Detterbeck, MD The Journal of Thoracic and Cardiovascular.

Sarah J. Gao, BS, Christopher D. Corso, MD, PhD, Elyn H

Now or Later: Evaluating the Importance of Chemotherapy Timing in Resectable Stage III (N2) Lung Cancer in the National Cancer Database Daniel J. Boffa,

Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind,

James B. Yu, MD, Lynn D. Wilson, MD, MPH, Frank C. Detterbeck, MD

National Cancer Database Report on Pneumonectomy Versus Lung-Sparing Surgery for Malignant Pleural Mesothelioma Vivek Verma, MD, Christopher A. Ahern,

The Role of Radiation Therapy in Malignant Thymoma: A Surveillance, Epidemiology, and End Results Database Analysis Annemarie T. Fernandes, BA, Eric.

Determinants of Complete Resection of Thymoma by Minimally Invasive and Open Thymectomy: Analysis of an International Registry Bryan M. Burt, MD, Xiaopan.

Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population- Based Study of 1686 Cases Åslaug Helland, MD, PhD, Steinar Solberg,

The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: Proposals for the T component for the Forthcoming (8th) Edition of the TNM Classification of.

Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review Swati Kulkarni, MD, Emily T. Vella,

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119 Wallace Akerley, MD, Jason McCoy, MS, Paul J.

Electronic Updates for JTO Readers

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Comparison of Segmentectomy and Lobectomy in Stage IA Adenocarcinomas

The Impact of Thymoma Histotype on Prognosis in a Worldwide Database

Surgical Management of Recurrent Thymic Epithelial Tumors: A Retrospective Analysis Based on the Japanese Nationwide Database Tetsuya Mizuno, MD, Meinoshin.

Frank Detterbeck, MD Journal of Thoracic Oncology

Should Patients with Extrapulmonary Small-Cell Carcinoma Receive Prophylactic Cranial Irradiation? Jarushka Naidoo, MB BcH BAO, MRCPI, Min Yuen Teo,

Distinct Clinical Course of EGFR-Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Standard Outcome Measures for Thymic Malignancies

Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline J Noble,

Propensity score–matched analysis of adjuvant chemotherapy for stage I non–small cell lung cancer Yasuhiro Tsutani, MD, PhD, Yoshihiro Miyata, MD, PhD,

Clinical Characteristics and Outcomes for Patients With Thymic Carcinoma: Evaluation of Masaoka Staging Anya M. Litvak, MD, Kaitlin Woo, MS, Sara Hayes,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Thymic carcinoma outcomes and prognosis: Results of an international analysis Usman Ahmad, MD, Xiaopan Yao, PhD, Frank Detterbeck, MD, James Huang, MD,

Prophylactic Cranial Irradiation for Patients with Surgically Resected Small Cell Lung Cancer Jianlin Xu, MD, Haitang Yang, MD, Xiaolong Fu, MD, Bo Jin,

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Postinduction positron emission tomography assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non–small cell.

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

Imaging Requirements in the Practice of Pulmonary Metastasectomy

Development of the International Thymic Malignancy Interest Group International Database: An Unprecedented Resource for the Study of a Rare Group of Tumors

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Andrew P. Dhanasopon, MD, Michelle C. Salazar, MD, Jessica R

Diffuse High Intensity PD–L1 Staining in Thymic Epithelial Tumors

Thymic Carcinoma Management Patterns among International Thymic Malignancy Interest Group (ITMIG) Physicians with Consensus from the Thymic Carcinoma.

Natural History and Factors Associated with Overall Survival in Stage IV ALK- Rearranged Non–Small Cell Lung Cancer Jose M. Pacheco, MD, Dexiang Gao,

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Assessment of Lymph Node Ratio to Replace the pN Categories System of Classification of the TNM System in Esophageal Squamous Cell Carcinoma Yingjie.

Prognostic Impact of Immune Microenvironment in Lung Squamous Cell Carcinoma Kyuichi Kadota, MD, PhD, Jun-ichi Nitadori, MD, PhD, Hideki Ujiie, MD, Daniel.

The Feasibility of Adjuvant Carboplatin and Docetaxel in Patients with Curatively Resected Non-small Cell Lung Cancer Thomas E. Stinchcombe, MD, Harry.

Determination of the minimum number of lymph nodes to examine to maximize survival in patients with esophageal carcinoma: Data from the Surveillance Epidemiology.

A Double-Blind Randomized Discontinuation Phase-II Study of Sorafenib (BAY 43– 9006) in Previously Treated Non–Small-Cell Lung Cancer Patients: Eastern.

Clinical Relevance of Our Multimodality Prognostic Score

Conditional Survival of Malignant Thymoma Using National Population-Based Surveillance, Epidemiology, and End Results (SEER) Registry (1973–2011) Ellen.

Pleurectomy/Decortication is Superior to Extrapleural Pneumonectomy in the Multimodality Management of Patients with Malignant Pleural Mesothelioma Loïc.

Primary Tumor Standardized Uptake Value Measured on F18-Fluorodeoxyglucose Positron Emission Tomography Is of Prediction Value for Survival and Local.

Thymic Carcinoma: A Cohort Study of Patients from the European Society of Thoracic Surgeons Database Enrico Ruffini, MD, Frank Detterbeck, MD, Dirk Van.

International Thymic Malignancies Interest Group: A Way Forward

Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study Giorgio V.

S-1 Treatment for Chemorefractory Thymic Carcinoma

Pruritus as a Paraneoplastic Symptom of Thymoma

Efficacy and Safety of Cisplatin/Pemetrexed Versus Cisplatin/Gemcitabine as First-Line Treatment in East Asian Patients with Advanced Non-small Cell Lung.

Epidemiology of Thymoma and Associated Malignancies

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Concurrent Chemotherapy and Short Course Radiotherapy in Patients with Stage IIIA to IIIB Non-small Cell Lung Cancer Not Eligible for Radical Treatment:

Robert Comis, MD, The Passing of a “Lung Man”

Presentation transcript:

Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database Sukhmani K. Padda, MD, Xiaopan Yao, PhD, Alberto Antonicelli, MD, Jonathan W. Riess, MD/MS, Yue Shang, PhD, Joseph B. Shrager, MD, Robert Korst, MD, Frank Detterbeck, MD, James Huang, MD, Bryan M. Burt, MD, Heather A. Wakelee, MD, Sunil S. Badve, MD Journal of Thoracic Oncology Volume 13, Issue 3, Pages 436-446 (March 2018) DOI: 10.1016/j.jtho.2017.11.118 Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Flow diagram. *Numbers do not add up to 373 because there is overlap among patients with missing information for each variable. ITMIG, International Thymic Malignancy Interest Group; PN/AI, paraneoplastic/autoimmune syndrome. Journal of Thoracic Oncology 2018 13, 436-446DOI: (10.1016/j.jtho.2017.11.118) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Cumulative incidence of recurrence in all patients with paraneoplastic/autoimmune syndrome (PN/AI(+)) versus without paraneoplastic/autoimmune syndrome (PN/AI(-)).CI, confidence interval. Journal of Thoracic Oncology 2018 13, 436-446DOI: (10.1016/j.jtho.2017.11.118) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 3 Overall survival (OS) in all patients with paraneoplastic/autoimmune syndrome (PN/AI(+)) versus without paraneoplastic/autoimmune syndrome (PN/AI(-)).HR, hazard ratio; CI, confidence interval. Journal of Thoracic Oncology 2018 13, 436-446DOI: (10.1016/j.jtho.2017.11.118) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 4 Overall survival (OS) with paraneoplastic/autoimmune syndrome (PN/AI(+)) versus without paraneoplastic/autoimmune syndrome (PN/AI(-)) in patients with thymoma (A) and patients with thymic carcinoma (B). HR, hazard ratio; CI, confidence interval. Journal of Thoracic Oncology 2018 13, 436-446DOI: (10.1016/j.jtho.2017.11.118) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions